UCB Pharma

UCB is a global biopharmaceutical company that discovers, develops, and commercializes medicines for serious neurological and immunological diseases. Its portfolio includes epilepsy therapies such as Keppra and Briviact, Cimzia for inflammatory conditions, and Bimzelx for psoriasis, sold through healthcare providers and payers. Founded in 1928 and headquartered in Brussels, it operates worldwide with manufacturing and quality operations, including a site in Saitama, Japan.